Alembic Pharmaceuticals Ltd on Monday announced its fiscal third quarter earnings report with profit at Rs 138.42 crore, down 23.29 per cent in comparison to Rs 180.45 crore during the same period of previous financial year.
According to the company’s statement, it posted revenue from operations at Rs 1,692.74 crore, up 3.81 per cent as against Rs 1,630.57 crore during the third quarter of FY24. The company EBITDA was down 2.1 per cent YoY at Rs 260 crore.
“In the current quarter, we faced market headwinds in the acute segment. However, other key therapies in our specialty business continued to outpace the market growth. To strengthen field force efficiency, we have enhanced Automation and AI, to upscale execution. This Transition has partly impacted quarter growth. We are confident to show a robust growth trajectory going forward. The US Business posted significant volume growth and the Ex-US markets continued to expand steadily. API Business is still under significant pricing pressure,” Shaunak Amin, MD, Alembic Pharmaceuticals Limited, said.
The India Branded Business grew 3 percent to Rs. 614 crores for the quarter. The Animal Health business grew 22 percent for the quarter with basket of strong brands driving outperformance. Specialty therapies recorded growth of 6 percent. The company made three launches during the quarter. New launches continue to do well along with promising future launches across key segments.
In the International Business, the US Generics grew 10 percent to Rs. 521 Crores for the quarter. Two launches in the US market during the quarter. Ex-US International Generics grew 10 percent to Rs. 299 Crores for the quarter. The company received seven ANDA approvals received during the quarter, 219 Cumulative ANDA approvals.